Beijing-based Chinese oncology research and development firm BeiGene (Beijing), Co., Ltd. has completed a new round of financing worth RMB600 million (US$97 million) co-led by Hillhouse Capital and an undisclosed U.S. public investment fund specializing in life sciences, according to a company announcement. CITIC Private Equity, the private equity arm of CITIC Capital Partners, together […]

Visit for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.

Visit the original source and full text: China Money Network